Company: ARTL
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001640334-25-002022
Chunk: 4

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
 

 5Table of Contents

ARTELO BIOSCIENCES, INC.

Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

  Nine Months Ended    September 30,    2025  2024        CASH FLOWS FROM OPERATING ACTIVITIES      Net loss $(8,713) $(6,048)Adjustments to reconcile net loss to net cash used in operating activities:        Stock-based compensation  774   617 Net change in fair value of trading marketable securities  -   (248)Net change in fair value of digital assets  (75)  - Non-cash lease expense  26   24 Amortization of debt discounts and debt issuance costs  137   - Changes in operating assets and liabilities:        Prepaid expenses and other current assets  111   518 Accounts payable and accrued liabilities  2,140   (629)Accounts payable - related parties  (29)  5 Accrued interest  46   - Fixed cash payments related to operating leases  (26)  (22)Net cash used in operating activities  (5,609)  (5,783)         CASH FLOWS FROM INVESTING ACTIVITIES        Purchase of digital assets  (250)  - Investment in trading marketable securities  -   (481)Proceeds from disposition of marketable securities  -   7,750 Net cash (used in) provided by investing activities  (250)  7,269          CASH FLOWS FROM FINANCING ACTIVITIES        Proceeds from issuance of common stock for cash, net  4,391   55 Proceeds from issuance of convertible notes, net  737   - Proceeds from exercise of warrants  132   - Net cash provided by financing activities  5,260   55          Effect of exchange rate changes on cash  (19)  1          Net change in cash and cash equivalents  (618)  1,542 Cash and cash equivalents - beginning of period  2,338   2,815 Cash and cash equivalents - end of period $1,720  $4,357